These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27687248)

  • 1. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
    Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
    Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics.
    Ilmer M; Mazurek N; Byrd JC; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
    Cell Death Dis; 2016 Aug; 7(8):e2337. PubMed ID: 27512958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
    Liao YM; Wang YH; Hung JT; Lin YJ; Huang YL; Liao GS; Hsu YL; Wu JC; Yu AL
    Breast Cancer Res; 2021 Jan; 23(1):5. PubMed ID: 33413566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
    Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
    J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
    Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
    Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.
    Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L
    J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
    Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
    BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
    Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
    BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
    Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
    Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Knockdown of XB130 restrains cancer stem cell-like phenotype through inhibition of Wnt/β-Catenin signaling in breast cancer.
    Xie T; Jiang C; Dai T; Xu R; Zhou X; Su X; Zhao X
    Mol Carcinog; 2019 Oct; 58(10):1832-1845. PubMed ID: 31219645
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy.
    Cui Y; Zhao M; Yang Y; Xu R; Tong L; Liang J; Zhang X; Sun Y; Fan Y
    Acta Biomater; 2022 Oct; 152():380-392. PubMed ID: 36028199
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells.
    Fritz AJ; Hong D; Boyd J; Kost J; Finstaad KH; Fitzgerald MP; Hanna S; Abuarqoub AH; Malik M; Bushweller J; Tye C; Ghule P; Gordon J; Frietze S; Zaidi SK; Lian JB; Stein JL; Stein GS
    J Cell Physiol; 2020 Oct; 235(10):7261-7272. PubMed ID: 32180230
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
    Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
    Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Friend leukemia virus integration 1 is a predictor of poor prognosis of breast cancer and promotes metastasis and cancer stem cell properties of breast cancer cells.
    Yan X; Yu Y; Li L; Chen N; Song W; He H; Dong J; Liu X; Cui J
    Cancer Med; 2018 Aug; 7(8):3548-3560. PubMed ID: 29869379
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.
    Shiraishi A; Tachi K; Essid N; Tsuboi I; Nagano M; Kato T; Yamashita T; Bando H; Hara H; Ohneda O
    Cancer Sci; 2017 Mar; 108(3):362-372. PubMed ID: 28012234
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells.
    Zhao Z; Lu P; Zhang H; Xu H; Gao N; Li M; Liu C
    Breast Cancer Res; 2014 Jul; 16(4):408. PubMed ID: 25056574
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells.
    Shimoda M; Sugiura T; Imajyo I; Ishii K; Chigita S; Seki K; Kobayashi Y; Shirasuna K
    BMC Cancer; 2012 Aug; 12():377. PubMed ID: 22931165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
    Al-Dhfyan A; Alhoshani A; Korashy HM
    Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
    Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
    Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
    Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
    Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.